Dimensional Fund Advisors LP boosted its holdings in Prothena Co. PLC (NASDAQ:PRTA) by 34.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,272,832 shares of the biotechnology company’s stock after buying an additional 328,166 shares during the period. Dimensional Fund Advisors LP owned approximately 3.19% of Prothena worth $13,110,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PRTA. BlackRock Inc. grew its position in shares of Prothena by 4.3% during the 3rd quarter. BlackRock Inc. now owns 3,311,388 shares of the biotechnology company’s stock valued at $43,313,000 after purchasing an additional 137,301 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Prothena by 1,145.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 101,599 shares of the biotechnology company’s stock valued at $1,329,000 after purchasing an additional 93,439 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Prothena by 2.2% during the 3rd quarter. Teachers Advisors LLC now owns 100,290 shares of the biotechnology company’s stock valued at $1,312,000 after purchasing an additional 2,157 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Prothena by 7,725.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 19,955 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 19,700 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Prothena by 82.9% during the 4th quarter. Bank of New York Mellon Corp now owns 373,072 shares of the biotechnology company’s stock valued at $3,842,000 after purchasing an additional 169,070 shares in the last quarter.

A number of research firms have recently commented on PRTA. BidaskClub lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research report on Thursday. Cantor Fitzgerald began coverage on shares of Prothena in a research report on Monday, March 4th. They set an “overweight” rating and a $13.77 price target for the company. Finally, Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, February 13th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Prothena currently has a consensus rating of “Hold” and a consensus target price of $31.47.

Shares of NASDAQ:PRTA opened at $10.70 on Friday. Prothena Co. PLC has a 52-week low of $8.63 and a 52-week high of $36.98. The firm has a market capitalization of $430.93 million, a P/E ratio of -2.96 and a beta of 2.53.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, February 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Prothena had a negative return on equity of 38.98% and a negative net margin of 16,297.91%. The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. As a group, analysts predict that Prothena Co. PLC will post -2.44 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Acquires 328,166 Shares of Prothena Co. PLC (PRTA)” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2019/04/19/dimensional-fund-advisors-lp-acquires-328166-shares-of-prothena-co-plc-prta.html.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Read More: Green Investing

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.